MedTrace Logo

Clinical Efficacy of Hormone Replacement Therapy in Treating Perimenopausal Women With MGD

NCT04962386 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2021-09-13

No results posted yet for this study

Summary

This project aims to evaluate the possible relationship between MGD and HRT in perimenopausal women

Conditions

  • Meibomian Gland Dysfunction

Interventions

DRUG

Hormone replacement therapy

HRT women were treated with an estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV, Weesp, the Netherlands).Take this medicine once a day.A course of treatment was defined as 28 days of continuous treatment.One white tablet containing 1mg of estradiol was taken daily for the first 14 days and one gray tablet containing 1mg of estradiol and 10 mg of dynamic progesterone was taken daily for the remaining 14 days.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Jin x ming, phd · Second Affiliated Hospital of Zhejiang University Hospital

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-06
Primary Completion
2022-03-06
Completion
2022-03-06

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04962386 on ClinicalTrials.gov